Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$13.22
-1.4%
$12.95
$7.69
$20.04
$73.52M0.5720,905 shs7,405 shs
Corium International, Inc. stock logo
CORI
Corium International
$12.68
$0.00
$7.17
$13.93
$459.65M0.87577,723 shsN/A
CytoDyn Inc. stock logo
CYDY
CytoDyn
$0.15
-6.3%
$0.17
$0.13
$0.42
$153.90M0.171.34 million shs790,017 shs
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1.63
-0.6%
$1.66
$1.33
$4.49
$87.17M1.77184,494 shs34,774 shs
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
$6.47
$6.47
$5.73
$8.75
N/AN/AN/AN/A
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-1.42%-11.45%+1.85%+24.62%+12.99%
Corium International, Inc. stock logo
CORI
Corium International
0.00%0.00%0.00%0.00%0.00%
CytoDyn Inc. stock logo
CYDY
CytoDyn
-3.16%+3.52%-8.14%-8.98%-50.63%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-0.61%-7.12%-6.32%+5.84%-59.45%
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
1.3022 of 5 stars
0.05.00.04.72.20.80.0
Corium International, Inc. stock logo
CORI
Corium International
N/AN/AN/AN/AN/AN/AN/AN/A
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.3051 of 5 stars
3.43.00.00.03.22.50.0
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.00
HoldN/AN/A
Corium International, Inc. stock logo
CORI
Corium International
N/AN/AN/AN/A
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.75
Moderate Buy$10.75559.51% Upside
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/A

Current Analyst Ratings

Latest CORI, SVA, CYDY, ASMB, and MIST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
3/22/2024
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
3/5/2024
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$6.00 ➝ $5.00
2/26/2024
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$7.16M10.12N/AN/A$7.50 per share1.76
Corium International, Inc. stock logo
CORI
Corium International
$31.86M14.43N/AN/A$0.45 per share28.18
CytoDyn Inc. stock logo
CYDY
CytoDyn
$270K551.59N/AN/A($0.12) per share-1.25
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1M86.63N/AN/A$0.50 per share3.26
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
$1.49BN/A$1.13 per share5.73$127.76 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$61.23M-$17.05N/AN/AN/AN/A-117.69%-72.43%5/2/2024 (Estimated)
Corium International, Inc. stock logo
CORI
Corium International
-$47.79M-$1.64N/AN/AN/A-155.21%-276.89%-57.52%N/A
CytoDyn Inc. stock logo
CYDY
CytoDyn
-$79.82M-$0.05N/AN/AN/AN/A-478.47%N/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$59.69M-$1.39N/AN/AN/AN/A-170.99%-64.45%5/9/2024 (Estimated)
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
$113.87MN/A0.00N/AN/AN/AN/A5/6/2024 (Estimated)

Latest CORI, SVA, CYDY, ASMB, and MIST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/15/2024Q3 2024
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/A-$0.01-$0.01-$0.01N/AN/A
3/21/2024Q4 2023
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$0.30-$0.32-$0.02-$0.32N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Corium International, Inc. stock logo
CORI
Corium International
N/AN/AN/AN/AN/A
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
N/AN/AN/AN/AN/A
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
3.41
3.41
Corium International, Inc. stock logo
CORI
Corium International
2.83
7.61
7.47
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/A
0.08
0.08
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.97
10.11
10.11
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
19.92%
Corium International, Inc. stock logo
CORI
Corium International
N/A
CytoDyn Inc. stock logo
CYDY
CytoDyn
5.06%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
86.18%
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
655.48 million5.26 millionOptionable
Corium International, Inc. stock logo
CORI
Corium International
N/A36.25 millionN/AOptionable
CytoDyn Inc. stock logo
CYDY
CytoDyn
12992.87 million985.82 millionNot Optionable
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
4753.15 million47.62 millionOptionable
Sinovac Biotech Ltd. stock logo
SVA
Sinovac Biotech
4,275N/AN/AOptionable

CORI, SVA, CYDY, ASMB, and MIST Headlines

SourceHeadline
Sinovac Amends Shareholder Rights PlanSinovac Amends Shareholder Rights Plan
businesswire.com - February 21 at 5:01 AM
Sinovac Amends Shareholder Rights PlanSinovac Amends Shareholder Rights Plan
businesswire.com - February 21 at 2:56 AM
Sinovac Board Rejects Partial Tender Offer By Alternative Liquidity Index - Quick FactsSinovac Board Rejects Partial Tender Offer By Alternative Liquidity Index - Quick Facts
markets.businessinsider.com - January 18 at 9:29 AM
Nepal to destroy 4 million doses of China’s Sinovac shots as China refuses to take back vaccinesNepal to destroy 4 million doses of China’s Sinovac shots as China refuses to take back vaccines
msn.com - January 3 at 9:48 AM
Sinovac Biotech Ltd SVASinovac Biotech Ltd SVA
morningstar.com - December 9 at 1:29 PM
Tag: SinovacTag: Sinovac
en.mercopress.com - November 25 at 7:40 PM
Pneumonia outbreak in China is no reason for alarm: WHOPneumonia outbreak in China is no reason for alarm: WHO
msn.com - November 24 at 3:49 PM
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 InjectionSINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
finance.yahoo.com - September 11 at 9:39 AM
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender OfferSinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
businesswire.com - September 5 at 5:01 AM
Sinovac Confirms Receipt of an Unsolicited Partial Tender OfferSinovac Confirms Receipt of an Unsolicited Partial Tender Offer
finance.yahoo.com - August 29 at 5:36 AM
Sinovac Announces Change of Legal Representative of Sinovac BeijingSinovac Announces Change of Legal Representative of Sinovac Beijing
finance.yahoo.com - August 28 at 9:34 AM
Sino­vacs Covid vac­cine sales nose­dive; Gra­cell trims pipeline, starts lu­pus studySino­vac's Covid vac­cine sales nose­dive; Gra­cell trims pipeline, starts lu­pus study
endpts.com - August 15 at 7:02 PM
SINOVAC Reports Unaudited First Half of 2023 Financial ResultsSINOVAC Reports Unaudited First Half of 2023 Financial Results
finance.yahoo.com - August 15 at 7:10 AM
SVA - Sinovac Biotech Ltd.SVA - Sinovac Biotech Ltd.
uk.finance.yahoo.com - July 20 at 10:42 PM
Director of Sinovacs intermediary institute said it did not close a deal with Uruguay for vaccineDirector of Sinovac's intermediary institute said it did not close a deal with Uruguay for vaccine
en.mercopress.com - July 7 at 9:27 AM
EU regulator starts review of China’s Sinovac vaccineEU regulator starts review of China’s Sinovac vaccine
politico.eu - June 27 at 8:45 AM
Chinas Sinovac vaccine is 50,38% effective according to leading Brazilian research centerChina's Sinovac vaccine is 50,38% effective according to leading Brazilian research center
en.mercopress.com - June 11 at 7:45 AM
SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 VaccinesSINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 Vaccines
finance.yahoo.com - May 10 at 8:27 AM
SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-FSINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F
finance.yahoo.com - May 1 at 10:29 AM
Uruguay acquired Pfizer and Sinovac vaccines; details will be announced SaturdayUruguay acquired Pfizer and Sinovac vaccines; details will be announced Saturday
en.mercopress.com - April 29 at 8:52 PM
Chile approves Coronavac for children aged six and olderChile approves Coronavac for children aged six and older
en.mercopress.com - April 25 at 8:19 PM
Chinese vaccine developer eyes production in ChileChinese vaccine developer eyes production in Chile
en.mercopress.com - April 22 at 8:54 AM
Sinovac Biotech Stock Soars (SVA)Sinovac Biotech Stock Soars (SVA)
thestreet.com - March 2 at 8:31 AM
SINOVAC Reports Unaudited First Half of 2022 Financial ResultsSINOVAC Reports Unaudited First Half of 2022 Financial Results
finance.yahoo.com - December 29 at 8:41 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Assembly Biosciences logo

Assembly Biosciences

NASDAQ:ASMB
Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Corium International logo

Corium International

NASDAQ:CORI
Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.
CytoDyn logo

CytoDyn

OTCMKTS:CYDY
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Milestone Pharmaceuticals logo

Milestone Pharmaceuticals

NASDAQ:MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Sinovac Biotech logo

Sinovac Biotech

NASDAQ:SVA
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.